DAX21.206 -0,5%ESt504.935 -0,6%Top 10 Crypto11,20 +3,2%Dow39.258 -1,0%Nas16.310 ±0,0%Bitcoin74.919 +1,6%Euro1,1347 -0,5%Öl67,96 +2,9%Gold3.320 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Siemens Energy ENER6Y Tesla A1CX3T RENK RENK73 Apple 865985 Amazon 906866 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Novo Nordisk A3EU6F Allianz 840400 BASF BASF11 Infineon 623100 Volkswagen (VW) vz. 766403 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht leichter ins Osterwochenende -- EZB senkt Leitzins -- Siemens Energy hebt Ausblick für 2025 an -- TSMC, NVIDIA, ASML, UnitedHealth, Hertz im Fokus
Top News
Alphabet-Aktie verliert: Nächstes Gericht in den USA wirft Google Monopolmissbrauch vor Alphabet-Aktie verliert: Nächstes Gericht in den USA wirft Google Monopolmissbrauch vor
DAX schließt nach EZB-Zinsentscheid auf rotem Terrain DAX schließt nach EZB-Zinsentscheid auf rotem Terrain
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

IDEAYA Biosciences Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
14,30 EUR -0,40 EUR -2,72 %
FSE
16,40 USD +0,21 USD +1,30 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.1,25 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PJPB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45166A1025

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIDYA

IDEAYA Biosciences Aktien News

DatumMeistgelesen
PR NewswireIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
finanzen.netIDEAYA Biosciences: So viel setzte das Unternehmen zuletzt um
PR NewswireIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
PR NewswireIDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
finanzen.netIDEAYA Biosciences: Das sind die jüngsten Quartalszahlen
PR NewswireIDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Leth...
PR NewswireIDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
PR NewswireIDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tu...
PR NewswireIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
PR NewswireIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)
PR NewswireIDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
finanzen.netIDEAYA Biosciences: So viel setzte das Unternehmen zuletzt um
PR NewswireIDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors
PR NewswireIDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy
PR NewswireIDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types
PR NewswireIDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors
PR NewswireIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
finanzen.netIDEAYA Biosciences stellte das Zahlenwerk zum vergangenen Quartal vor
PR NewswireIDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Wer­bung

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.